Saatja:
[email protected] <
[email protected]>
Saaja:
[email protected]
Teema: Ares(2019)2553091_Referral under Article 31 of Directive 2001/83/EC – High concentration estradiol containing medicinal products for topical use – Commission Implementing Decision of 19 August 2014 C(2014)6030
Our reference: Ares(2019)2553091
Dear Sirs/Madams,
Please find attached a letter on the above mentioned subject.
Kind regards,
Unit “Medicines: policy, authorisation and monitoring“
[logo-ce-horizontal-en-quadri-jpg24]
European Commission
DG Health and Food Safety
_____________
This message represents solely the views of its author and can not be regarded as the official position of the Commission. It is intended solely for the person to whom it is addressed and may contain confidential information. If you have received this message in error, please notify me as soon as possible.
Saatja: Webdesktop <
[email protected]>
Saadetud: 11.04.2019 18:10
Adressaat: SM Info <
[email protected]>; Elen Ohov <
[email protected]>; info ravimiamet ee
<
[email protected]>; Kristin Raudsepp <
[email protected]>
Koopia: <
[email protected]>
Teema: Webdesktop: Kiri nr 10.2-12.T/489 / Referral under Article 31 of Directive
2001/83/EC (uue hindamismenetluse algatamine)
Manused: 489.pdf; 489_Edastamismeil.msg
Tere
Edastan Euroopa Komisjoni kirja.
Reg. number: 10.2-12.T/489
Reg. kuupäev: 11.04.2019
Sisu: Referral under Article 31 of Directive 2001/83/EC – High concentration estradiol
containing medicinal products for topical use – Commission Implementing Decision of 19
August 2014 C(2014)6030 – Judgement of the European Court of Justice in case C-680/16P
of 27 March 2019 - New referral procedure
Heade soovidega
Tiiu Noobel
sekretär EV AEEL juures
Ref. Ares(2019)2553091 - 11/04/2019
EUROPEAN COMMISSION
DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY
Health systems, medical products and innovation
Medicines: policy, authorisation and monitoring
Head of Unit
Brussels,
sante.ddg1.b5/FS/an(2019)2835813
By email only
Dear Sirs/Madams,
Subject: Referral under Article 31 of Directive 2001/83/EC – High concentration
estradiol containing medicinal products for topical use – Commission
Implementing Decision of 19 August 2014 C(2014)6030 – Judgement of
the European Court of Justice in case C-680/16P of 27 March 2019
With this letter we would like to inform you that Commission Implementing Decision
C(2014)6030 final of 19 August 2014 has been partially annulled by the judgement of the
European Court of Justice of 27 March 2019.
1. BACKGROUND
By its implementing decision of 19 August 2014, the Commission completed a Union interest
referral under Article 31 on high-concentration estradiol containing products. Based on the
scientific opinion of the European Medicines Agency it was found that the authorised use of
the product should be restricted and product information should be updated to better reflect
the product’s risk. In view of those changes to the benefit-risk balance, Member States were
requested to amend the national marketing authorisations concerned.
Two of the marketing authorisation holders concerned brought the Commission to court and
requested the annulment of the Commission decision.
By its judgment of 27 March 2019, the Court of Justice decided to partially annul the
Commission decision. According to the Court, taking into account the particular
circumstances of the case, the handling of the review of the concerned products by the
responsible committee of the European Medicines Agency had not ensured sufficient
guarantees to exclude any legitimate doubts as to compliance with the obligation of
impartiality as enshrined in Article 41 of the Charter (case C-680/16P).
Commission européenne, B-1049 Bruxelles / Europese Commissie, B-1049 Brussel - Belgium. Telephone: (32-2) 299 11 11.
E-mail:
[email protected]
However, it is important to stress that the Court did not annul the Commission Implementing
Decision in its entirety, but only:
"in so far as that decision directs the Member States to comply with the requirements which it
stipulated for the medicinal products, for which Dr. August Wolff GmbH & Co. KG
Arzneimittel and Remedia d.o.o. hold marketing authorisation, with 0.01% estradiol by
weight for topical use referenced and non-referenced in Annex I thereto, excluding the
restriction that the medicinal products with 0.01% estradiol by weight for topical use
referenced in that annex may still be used by vaginal application only."
It follows that the annulment is limited in content and limited in scope, as it only applies to
the marketing authorisations of the companies Dr. August Wolff GmbH & Co. KG
Arzneimittel and Remedia d.o.o.
Given that the Commission Implementing Decision was addressed to Member States,
Member States are asked to review in due course the national decisions they have taken at the
time to implement it. The partial annulment of the Commission Decision may directly affect
the validity of those national decisions to vary the marketing authorisations concerned.
Hence, the concerned Member States are required to take the necessary steps to fully
implement the judgment.
2. NEXT STEPS
The partial annulment of the Commission Decision leads to the invalidation of some of the
restrictive measures that have been taken as the outcome of the above described review, even
if the scientific assessment of the products was not put into question by the Court of Justice in
its judgment.
Therefore the European Commission is concerned that the identified safety risks are no longer
appropriately addressed and that patients are put at a risk. As a consequence, it has launched a
new referral procedure under Article 31 of Directive 2001/83/EC.
Yours sincerely,
[Electronically signed]
p.o. Florian Schmidt
Olga Solomon
2
Electronically signed on 11/04/2019 13:41 (UTC+02) in accordance with article 4.2 (Validity of electronic documents) of Commission Decision 2004/563